Moderna stock falls 6% in premarket: here's why

Moderna stock MRNA fell nearly 6% in premarket trading on Wednesday after Citi downgraded the biotech company to ‘Sell' from ‘Hold', citing concerns that its recent valuation is difficult to justify. ...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。